Hematology Hawk Kim Favorite Doctor
- SpecialtyLeukemia, bone marrow failure
- Site
Schedule
| Week | M | T | W | T | F | S |
|---|---|---|---|---|---|---|
| AM | Present | |||||
| PM |
Clinical Interests
Acute myeloid leukemia
Chronic myeloid leukemia
Myelodysplastic syndromes
Aplastic anemia
Anemia
Thrombocytopenia
Leukopenia
Splenomegaly
Rare blood diseses
Education
| 1995 | Hanyang University College of Medicine, MD |
|---|---|
| 1999 | Hanyang University Graduate College of Medicine, M.S |
| 2007 | Ulsan University Graduate College of Medicine, Ph.D. |
Career
| 1995 | Hanyang University Hospital, Intern |
|---|---|
| 1996 | Department of Internal Medicine, Hanyang University Hospital, Resident |
| 2000 | Army Medical Center Hospital, Medical officer |
| 2003 | Asan Medical Center, Clinical Instructor |
| 2005 | Ulsan University Hospital, Professor |
| 2017~ | Gachon University Gil Medical Center, Professor |
Community
Training
| 2008 | M. D. Anderson Cancer Center |
|---|
License
| 1995 | Medical License |
|---|---|
| 2000 | Internal Medicine Specialist |
| 2006 | Hematology Oncology Specialist |
Paper
| 2019 | Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukemia in the chronic phase (RERISE). |
|---|---|
| 2019 | Age and remission induction therapy for acute myeloid leukemia (AML): from Korean AML registry |
| 2019 | Prospective randomized trial comparing two doses of rabbit antithymocyte globulin in patients with severe aplastic anemia. |
| 2019 | Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome. |
| 2019 | Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia (AML) in older adults and the role of a mini nutritional assessment short form (MNA-SF). |
